Skip to main content
Equibles
INDV logo

INDV · Indivior Pharmaceuticals, Inc. · Webcasts, Transcripts & Audio

Track INDV — free

Use INDV with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research INDV.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$35.71 +0.33 (+0.93%) At close · Oct 2
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$4.23B
Shares
118.01M
Volume · Oct 2 1.67M Avg daily vol (3M) 2.04M

Indivior Pharmaceuticals, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Indivior Pharmaceuticals, Inc. (INDV), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▼6.3% $266.00M $47.00M '25 Q1 25-04-24 ▲1% $302.00M $18.00M '25 Q2 25-07-31 ▲2.3% $314.00M $42.00M '25 Q3 25-10-30 ▲19.8% $357.00M $103.00M '25 Q4 26-02-26 ▲19.2% $317.00M $89.00M '26 Q1 26-04-30 LATEST ▲13.6% $343.00M $122.00M '26 Q2 26-08-03
Earnings call
FY26 · Q2
2026-08-03
Indivior Pharmaceuticals, Inc. (INDV) Q2 2026 Earnings Call
Revenue
$343.00M
▲ 13.6% YoY
Diluted EPS
$0.98
▲ 600% YoY
Gross margin
85.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-03
Indivior Pharmaceuticals, Inc. (INDV) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-04-30
Indivior Pharmaceuticals, Inc. (INDV) Q1 2026 Earnings Call Transcript
Confident tone SUBLOCADE U.S. growth 2026 financial guidance raise Pipeline setbacks
Revenue
$317.00M
▲ 19.2% YoY
Diluted EPS
$0.69
▲ 81.6% YoY
Gross margin
87.4%
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
Indivior Pharmaceuticals, Inc. (INDV) Q4 2025 Earnings Call Transcript
Confident tone SUBLOCADE Commercial Performance Indivior Action Agenda / Phase 2 Accelerate 2026 Financial Guidance and Capital Deployment
Revenue
$357.00M*
▲ 19.8% YoY
Gross margin
82.1%
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-10-30
Indivior Pharmaceuticals, Inc. (INDV) Q3 2025 Earnings Call Transcript
Confident tone SUBLOCADE commercial execution and growth Indivior Action Agenda phasing (Phase I, II, III) Organizational simplification and cost reduction
Revenue
$314.00M
▲ 2.3% YoY
Diluted EPS
$0.33
▲ 106.2% YoY
Gross margin
73.2%
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-07-31
Indivior Pharmaceuticals, Inc. (INDV) Q2 2025 Earnings Call Transcript
Positive tone SUBLOCADE U.S. commercial execution Indivior Action Agenda (operational restructuring) Medicaid and policy environment
Revenue
$302.00M
▲ 1% YoY
Diluted EPS
$0.14
Gross margin
82.8%
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-04-24
Indivior Pharmaceuticals, Inc. (INDV) Q1 2025 Earnings Call Transcript
Balanced tone SUBLOCADE performance and stabilization Justice system funding headwinds Suboxone Film generic competition
Revenue
$266.00M
▼ 6.3% YoY
Diluted EPS
$0.38
▼ 15.6% YoY
Gross margin
83.1%
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–7 of 7 webcasts
Key facts CIK 1625297 CUSIP 45579U109 13F (30d) 6 filings 6 filers Visit website Investor relations